LuciUpa 15 MG (Upadacitinib)

Description

Upadacitinib

Each film-coated tablet contains: Upadacitinib… 15 mg.

INDICATION

LuciUpa is a Janus kinase (JAK) inhibitor indicated for the treatment of: • Adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. • Adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. • Adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers.

DOSAGE AND USE

• Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis the recommended dosage is 15 mg once daily. • Ulcerative Colitis the recommended induction dosage is 45 mg once daily for 8 weeks. The recommended maintenance dosage is 15 mg once daily.

STORAGE

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY

LUCIUS PHARMACEUTICALS(LAO) CO., LTD. No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING

Keep medicine out of reach of Children. Do not administer LuciUpa during Pregnancy and Lactation.